Nanjing Vazyme Biotech Hits Day High with 13.17% Surge

Nanjing Vazyme Biotech Co., Ltd. has experienced a significant surge in its stock price, gaining 13.17% on June 18, 2026. The stock reached an intraday high of CNY 15.74, marking a notable performance against the backdrop of the China Shanghai Composite, which declined by 0.43% on the same day. In terms of weekly performance, Nanjing Vazyme has shown an impressive increase of 11.97%, while the broader market index rose by only 2.6%. However, the company's performance over the past month reflects a slight decline of 2.03%, contrasting with the Shanghai Composite's marginal drop of 0.99%. Despite the recent uptick, Nanjing Vazyme's year-to-date performance stands at 2.08%, slightly trailing the Shanghai Composite's 3.06%. Over the past year, the stock has faced challenges, with a decline of 5.65%, while the Shanghai index has gained 20.71%. With a market capitalization of CNY 6,794 million, Nanjing Vazyme operates within the pharmaceuticals and biotechnology sector, characterized by a price-to-book ratio of 1.79 and a negative return on equity of -1.86%.